ARCHIVES

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

This article is from The Cancer Letter archive.

Vol. 33 No. 18 | May 11, 2007

Download PDF Visit The Full Archive

Related Articles

IOM: No Negligence In FIAU Clinical Trial That Killed Five

March 31, 1995

Centocor Withdraws Yondelis After FDA Calls for New Study

April 29, 2011

NCI Programs: 15 New Grants Awarded In Survivor Research

October 9, 1998

Cooperative Groups: Committee Formed To Implement Armitage Report Had A Rough Start

June 12, 1998

Review Of Organ Site Program Requested By NCAB Set For Nov. 23-25; Eight Member Committee Named

August 21, 1981

Yates Identifies “Probable”, “Potential” Core Grant Applicants

January 16, 1987